This study focuses on patients with Pulmonary Arterial Hypertension, a condition where blood pressure in the arteries of the lungs is abnormally high. The study aims to compare two different treatment approaches: a combination therapy using two medications versus treatment with a single medication plus placebo. The medications being studied are ambrisentan and tadalafil, which are both taken by mouth in the form of tablets.
The research will examine which treatment strategy is more effective at controlling the disease after 6 months in newly diagnosed patients who also have heart and blood vessel-related health conditions. During the study, participants will be divided into two groups. One group will receive both ambrisentan and tadalafil, while the other group will receive tadalafil and a placebo. The treatment period will last approximately 175 days.
Throughout the study, various aspects of the participants’ health will be monitored, including their ability to exercise, heart function, and overall well-being. The medications being tested are already approved for medical use, but they will be studied in a specific combination to determine if this approach provides better results for patients with additional cardiovascular health conditions.
France 
